ZYUS Life Sciences Corporation Announces Closing of Additional Secured Loan

Executive Summary

• ZYUS Life Sciences Corp. closed an additional secured loan of CA$0.5 million from an independent director (the “Director Lender”) on October 20, 2025.
• The loan is secured by a general security agreement, bears 12% annual interest, matures on October 31, 2027 and is prepaid without penalty.
• As consideration, the Director Lender received 724,637 common share purchase warrants at $0.69 per share, exercisable for two years (subject to acceleration provisions).

Key Details

• Loan Amount & Terms – CA$0.5 million secured loan; interest rate 12% per annum; payable on maturity (Oct 31 2027); pre‑payable at any time without penalty.
• Security – General security agreement covering all assets of ZYUS Inc., subject to an exception for certain assets; pending TSX Venture Exchange approval.
• Related Prior Transaction – Adds to a previously announced CA$1.5 million loan from the same Director Lender dated October 17, 2025.
• Warrant Issuance – 724,637 common share purchase warrants issued to the Director Lender; exercise price $0.69 per share; expiry two years from issuance unless accelerated.
• Acceleration Triggers –
• If VWAP > $3.00 for five consecutive trading days during the warrant exercise period, ZYUS may accelerate expiry to 30 days after a news‑release notice.
• If any principal amount of the loans is repaid in full before October 20 2026, warrants expire 12 months from issuance.
• Use of Proceeds – General working capital, primarily to advance clinical research on the Phase 2 trial for Trichomylin® softgel capsules.
• Regulatory & Governance – Transaction qualifies as a related‑party transaction under MI 61‑101; Director Lender abstained from audit committee and board approvals; exemption relied upon for valuation and minority shareholder approval requirements.
• Disclosure – No material change report filed prior to the loan because terms were not finalized until shortly before closing; all independent directors have approved the transaction.

Notable Quotes

(No direct quotes provided in the release.)